PF-Atlas › Clinical Trials › NCT04244825
Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
BLD-2660 · Phase 2
Registry ID
NCT04244825
Phase
Phase 2
Status
Withdrawn
Drug / intervention
BLD-2660
Sponsor
Blade Therapeutics
Start
2019-12-15
Locations
1
About this trial
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT04244825 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.